Related Experiment Videos

A randomized, comparative, multicentric evaluation of atenolol/amlodipine combination with atenolol alone in

Anil Pareek1, Harsha Salkar, Pradeep Mulay

  • 1Medical Affairs & Clinical Research, Ipca Laboratories Limited, Kandivli Industrial Estate, Kandivli, Mumbai, India. anilpareek@ipca.co.in

American Journal of Therapeutics
|June 19, 2009
PubMed

Insights

Atenolol/amlodipine combination therapy significantly lowers blood pressure more effectively than atenolol monotherapy for essential hypertension. This combination treatment leads to better blood pressure control and higher response rates in patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Hypertension Research

Background:

  • Elevated blood pressure (hypertension) is a major risk factor for cardiovascular diseases.
  • Effective blood pressure control is crucial for reducing cardiovascular endpoints.
  • Atenolol and amlodipine are common antihypertensive agents.

Purpose of the Study:

  • To compare the efficacy of atenolol/amlodipine combination therapy versus atenolol monotherapy in reducing systolic and diastolic blood pressure.
  • To assess the response rate and tolerability of both treatment regimens.
  • To evaluate the achievement of normalized blood pressure levels.

Main Methods:

  • A 12-week, randomized, comparative, multicentric study.
  • Patients received either atenolol/amlodipine or atenolol monotherapy, with dose escalation for non-responders.
  • Blood pressure measurements, response rates, and tolerability were assessed.

Main Results:

  • Combination therapy demonstrated superior reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to monotherapy at both low and high doses.
  • The combination group showed significantly higher response rates.
  • More patients in the combination group achieved normalized blood pressure (SBP < 120 mmHg and DBP < 80 mmHg).

Conclusions:

  • Once-daily atenolol/amlodipine fixed-dose combination therapy provides superior antihypertensive efficacy over atenolol monotherapy.
  • This combination is effective in achieving blood pressure normalization in patients with mild-to-moderate essential hypertension.
  • The findings support the use of atenolol/amlodipine combination for improved hypertension management.

Related Concept Videos

Antihypertensive Drugs: Types of &#946;-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: &#593; and &#946;-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...